ClinicalTrials.gg
CompletedNCT04707469PIONEER PLUSUpdated Dec 9, 2025Results posted

Research Study to Compare Three Doses of Semaglutide Tablets Taken Once Daily in People With Type 2 Diabetes

A Phase 3 interventional study of Oral semaglutide in Diabetes Mellitus, Type 2, sponsored by Novo Nordisk A/S. Completed at 228 sites in 15 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-09.

Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,606
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 163 studies testing semaglutide in Diabetes Mellitus, Type 2 — 35 open to participants now, 45 under way, 9 of them phase 3. Semaglutide · Diabetes Mellitus, Type 2.

Enrollment
9th of 163
1,606 · median 104
Started
2021
with 9 others
Phase 3
57 of 163
7 open now
Registered
82nd of 163
by date
Lead sponsor
89 of 163
Novo Nordisk A/S

Among the 163 studies testing semaglutide in Diabetes Mellitus, Type 2, this one is the 9th largest by enrollment, is one of 10 that started in 2021, is one of 57 in phase 3, and was the 82nd registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

35 of the 163 studies testing semaglutide in Diabetes Mellitus, Type 2 are open now, in 12 countries. Recruiting first, the newest first:

30 more — sign in →

By country, each count listing its studies:

All 35 open studies →

About semaglutide

Semaglutide: first FDA approval 2017 (OZEMPIC), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 163 studies testing semaglutide in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

This study compares three doses of once daily semaglutide tablets in people with type 2 diabetes who were previously treated with other oral anti-diabetic medicines. Participants will be initiated on the lowest starting dose of 3 mg and gradually increased until they reach the final trial dose of 14 mg, 25 mg or 50 mg once daily semaglutide tablets. The final three doses will be randomized (i.e., decided by chance). Participants will be administered one tablet per day for 68 weeks. Women cannot take part if they are pregnant, breast-feeding or planning to become pregnant during the study period. Women who can get pregnant will be checked for pregnancy via urine tests. Once daily semaglutide tablets (3 mg, 7 mg and 14 mg) are approved for the treatment of type 2 diabetes in the US, in the EU and in some other countries, under the brand name Rybelsus®.

03

Conditions studied

  • Diabetes Mellitus, Type 2
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female, age above or equal to 18 years at the time of signing .
  • Diagnosed with type 2 diabetes mellitus at least 180 days prior to the day of screening.
  • of 8.0-10.5% (64-91 mmol/mol) (both inclusive).
  • equal to or above 25 kg/m\^2
  • Stable daily dose(s) for 90 days prior to the day of screening of any of the following treatment regimens:
  • No more than 3 of the following oral anti-diabetic drugs and at least 1 marked with a *:

    • Metformin (equal to or above1500 mg or maximum tolerated or effective dose).
    • Sulfonylureas (SU) (equal to or above half of the maximum approved dose according to local label or maximum tolerated or effective dose).
    • Sodium/glucose cotransporter 2 (SGLT2) inhibitors (maximum tolerated dose).
  • Dipeptidyl peptidase-4 (DPP-4) inhibitors (maximally indicated dose as per local label).
  • Subjects, on treatment with stable dose of DPP-4 inhibitors at inclusion, must be willing to discontinue DPP-4 inhibitor treatment at randomisation (with no wash-out).

Exclusion criteria

Exclusion Criteria:

  • Treatment with any medication indicated for the treatment of diabetes or obesity other than stated in the inclusion criteria within the past 90 days prior to the day of screening. However, short term insulin treatment for a maximum of 14 days prior to the day of screening is allowed.
  • Renal impairment measured as estimated (eGFR) value of below 30 mL/min/1.73 m\^2 according to Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) creatinine equation as defined by kidney disease improving global outcomes (KDIGO 2012) classification.
  • Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Verified by a fundus examination performed within the past 90 days prior to screening or in the period between screening and randomisation. Pharmacological pupil-dilation is a requirement unless using a digital fundus photography camera specified for non-dilated examination.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,606 participants (actual)

Study arms

  • Experimental
    Oral semaglutide 50 mg

    Participants will receive once daily semaglutide tablets in a dose escalating manner for 68 weeks: 3 mg (week 1-4), 7 mg (week 5-8), 14 mg (week 9-12), 25 mg (week 13-16) and 50 mg (week 17-68).

    Drug: Oral semaglutide

  • Experimental
    Oral semaglutide 25 mg

    Participants will receive once daily semaglutide tablets in a dose escalating manner for 68 weeks: 3 mg (week 1-4), 7 mg (week 5-8), 14 mg (week 9-12) and 25 mg (week 13-68).

    Drug: Oral semaglutide

  • Active comparator
    Oral semaglutide 14 mg

    Participants will receive once daily semaglutide tablets in a dose escalating manner for 68 weeks: 3 mg (week 1-4), 7 mg (week 5-8) and 14 mg (week 9-68).

    Drug: Oral semaglutide

Interventions

  • Participants will receive once daily semaglutide tablets (oral administration) in a dose escalating manner for 68 weeks.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Glycated Haemoglobin (HbA1c) (Week 52)

    Change from baseline (week 0) in glycosylated haemoglobin (HbA1c) was evaluated at week 52. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of additional anti-diabetic medication or discontinuation of trial treatment. Percentage point refers to arithmetic difference between two percentages.

    Time frame: Baseline (week 0), week 52

Secondary outcomes

  1. Change From Baseline in Body Weight (Week 52)

    Change from baseline (week 0) in body weight was evaluated at week 52. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of additional anti-diabetic medication or discontinuation of trial treatment.

    Time frame: Baseline (week 0), week 52

  2. Change From Baseline in HbA1c (Week 68)

    Change from baseline (week 0) in HbA1c was evaluated at week 68. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of additional anti-diabetic medication or discontinuation of trial treatment. Percentage point refers to arithmetic difference between two percentages.

    Time frame: Baseline (week 0), week 68

  3. Change From Week 12 in HbA1c (Week 52)

    Change in HbA1c was evaluated from week 12 to week 52. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of additional anti-diabetic medication or discontinuation of trial treatment. Percentage point refers to arithmetic difference between two percentages.

    Time frame: Week 12, Week 52

  4. Change From Baseline in Fasting Plasma Glucose (FPG) (Week 52)

    Change from baseline (week 0) in fasting plasma glucose (FPG) was evaluated at week 52. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of additional anti-diabetic medication or discontinuation of trial treatment.

    Time frame: Baseline (week 0), week 52

  5. Change From Baseline in FPG (Week 68)

    Change from baseline (week 0) in FPG was evaluated at week 68. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of additional anti-diabetic medication or discontinuation of trial treatment.

    Time frame: Baseline (week 0), week 68

  6. Percentage of Participants Who Achieved HbA1c Less Than (<) 7.0 (Percent [%]) (Week 52)

    Percentage of participants who achieved HbA1c \<7.0 % at week 52 are presented. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of additional anti-diabetic medication or discontinuation of trial treatment.

    Time frame: At week 52

  7. Percentage of Participants Who Achieved HbA1c < 7.0 % (Week 68)

    Percentage of participants who achieved HbA1c \<7.0 % at week 68 are presented. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of additional anti-diabetic medication or discontinuation of trial treatment.

    Time frame: At week 68

  8. Percentage of Participants Who Achieved HbA1c Less Than or Equal to (<=) 6.5 % (Week 52)

    Percentage of participants who achieved HbA1c \<=6.5 % at week 52 are presented. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of additional anti-diabetic medication or discontinuation of trial treatment.

    Time frame: At week 52

  9. Percentage of Participants Who Achieved HbA1c <= 6.5 % (Week 68)

    Percentage of participants who achieved HbA1c \<=6.5 % at week 68 are presented. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of additional anti-diabetic medication or discontinuation of trial treatment.

    Time frame: At week 68

  10. Time to Event Analyses of Rescue Medication

    Time to event analyses of rescue medication was evaluated from baseline (week 0) to week 68. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of additional anti-diabetic medication or discontinuation of trial treatment.

    Time frame: Baseline (week 0), week 68

  11. Change From Baseline in Body Weight (Week 68)

    Change from baseline (week 0) in body weight was evaluated at week 68. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of additional anti-diabetic medication or discontinuation of trial treatment.

    Time frame: Baseline (week 0), week 68

  12. Percentage Change From Baseline in Body Weight (Week 52)

    Percentage change from baseline (week 0) in body weight was evaluated at week 52. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of additional anti-diabetic medication or discontinuation of trial treatment.

    Time frame: Baseline (week 0), week 52

  13. Percentage Change From Baseline in Body Weight (Week 68)

    Percentage change from baseline (week 0) in body weight was evaluated at week 68. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of additional anti-diabetic medication or discontinuation of trial treatment.

    Time frame: Baseline (week 0), week 68

  14. Percentage Change From Week 12 in Body Weight (Week 52)

    Percentage change in body weight was evaluated from week 12 to week 52. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of additional anti-diabetic medication or discontinuation of trial treatment.

    Time frame: Week 12, Week 52

  15. Change From Baseline in Body Mass Index (BMI) (Week 52)

    Change from baseline (week 0) in body mass index (BMI) was evaluated at week 52. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of additional anti-diabetic medication or discontinuation of trial treatment.

    Time frame: Baseline (week 0), week 52

  16. Change From Baseline in BMI (Week 68)

    Change from baseline (week 0) in BMI was evaluated at week 68. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of additional anti-diabetic medication or discontinuation of trial treatment.

    Time frame: Baseline (week 0), week 68

  17. Change From Baseline in Waist Circumference (Week 52)

    Change from baseline (week 0) in waist circumference was evaluated at week 52. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of additional anti-diabetic medication or discontinuation of trial treatment.

    Time frame: Baseline (week 0), week 52

  18. Change From Baseline in Waist Circumference (Week 68)

    Change from baseline (week 0) in waist circumference was evaluated at week 68. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of additional anti-diabetic medication or discontinuation of trial treatment.

    Time frame: Baseline (week 0), week 68

  19. Percentage of Participants Who Achieved Weight Loss Greater Than or Equal to (>=) 5 % (Week 52)

    Percentage of participants who achieved weight loss \>= 5 % at week 52 are presented. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of additional anti-diabetic medication or discontinuation of trial treatment.

    Time frame: At week 52

  20. Percentage of Participants Who Achieved Weight Loss >= 5 % (Week 68)

    Percentage of participants who achieved weight loss \>= 5 % at week 68 are presented. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of additional anti-diabetic medication or discontinuation of trial treatment.

    Time frame: At week 68

  21. Percentage of Participants Who Achieved Weight Loss >= 10 % (Week 52)

    Percentage of participants who achieved weight loss \>= 10 % at week 52 are presented. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of additional anti-diabetic medication or discontinuation of trial treatment.

    Time frame: At week 52

  22. Percentage of Participants Who Achieved Weight Loss >= 10 % (Week 68)

    Percentage of participants who achieved weight loss \>= 10 % at week 68 are presented. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of additional anti-diabetic medication or discontinuation of trial treatment.

    Time frame: At week 68

  23. Change From Baseline in Total Cholesterol (Week 52)

    Change from baseline (week 0) in total cholesterol was evaluated at week 52. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of additional anti-diabetic medication or discontinuation of trial treatment.

    Time frame: Baseline, Week 52

  24. Change From Baseline in Total Cholesterol (Week 68)

    Change from baseline (week 0) in total cholesterol was evaluated at week 68. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of additional anti-diabetic medication or discontinuation of trial treatment.

    Time frame: Baseline, Week 68

  25. Change From Baseline in Low Density Lipoproteins (LDL) (Week 52)

    Change from baseline (week 0) in LDL was evaluated at week 52. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of additional anti-diabetic medication or discontinuation of trial treatment.

    Time frame: Baseline, Week 52

  26. Change From Baseline in LDL (Week 68)

    Change from baseline (week 0) in LDL was evaluated at week 68. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of additional anti-diabetic medication or discontinuation of trial treatment.

    Time frame: Baseline, Week 68

  27. Change From Baseline in High Density Lipoproteins (HDL) (Week 52)

    Change from baseline (week 0) in HDL was evaluated at week 52. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of additional anti-diabetic medication or discontinuation of trial treatment.

    Time frame: Baseline, Week 52

  28. Change From Baseline in HDL (Week 68)

    Change from baseline (week 0) in HDL was evaluated at week 68. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of additional anti-diabetic medication or discontinuation of trial treatment.

    Time frame: Baseline, Week 68

  29. Change From Baseline in Triglycerides (Week 52)

    Change from baseline (week 0) in triglycerides was evaluated at week 52. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of additional anti-diabetic medication or discontinuation of trial treatment.

    Time frame: Baseline, Week 52

  30. Change From Baseline in Triglycerides (Week 68)

    Change from baseline (week 0) in triglycerides was evaluated at week 68. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of additional anti-diabetic medication or discontinuation of trial treatment.

    Time frame: Baseline, Week 68

  31. Number of Adverse Events

    An adverse event (AE) defined as any unfavourable and unintended sign, including an abnormal laboratory finding, symptom or disease (new or exacerbated) temporally associated with the use of an investigational medicinal products (IMP). Results are based on the data from the on-treatment observation period, which was the time period when a participant was on trial treatment, including any period after initiation of rescue medication.

    Time frame: From baseline (week 0) up to week 73

  32. Number of Clinically Significant Hypoglycaemic Episodes (Level 2) (<3.0 mmol/L (54 Milligram Per Decilitre [mg/dL]) or Severe Hypoglycaemic Episodes (Level 3)

    Hypoglycaemic episodes were classified according to the American Diabetes Association 2018/ International Hypoglycaemia Study Group 2017, where glycemic criteria for level 2 was \< 3.0 mmol/L (54 mg/dL) and level 3 had no specific glucose threshold. Results are based on the data from the on-treatment observation period, which was the time period when a participant was on trial treatment, including any period after initiation of rescue medication.

    Time frame: From baseline (week 0) up to week 68

  33. Change From Baseline in Systolic Blood Pressure (Week 52)

    Change from baseline (week 0) in systolic blood pressure at week 52 are presented. Results are based on the data from the on-treatment observation period, which was the time period when a participant was on trial treatment, including any period after initiation of rescue medication.

    Time frame: Baseline (week 0), week 52

  34. Change From Baseline in Systolic Blood Pressure (Week 68)

    Change from baseline (week 0) in systolic blood pressure at week 68 are presented. Results are based on the data from the on-treatment observation period, which was the time period when a participant was on trial treatment, including any period after initiation of rescue medication.

    Time frame: Baseline (week 0), week 68

  35. Change From Baseline in Diastolic Blood Pressure (Week 52)

    Change from baseline (week 0) in diastolic blood pressure at week 52 are presented. Results are based on the data from the on-treatment observation period, which was the time period when a participant was on trial treatment, including any period after initiation of rescue medication.

    Time frame: Baseline (week 0), week 52

  36. Change From Baseline in Diastolic Blood Pressure (Week 68)

    Change from baseline (week 0) in diastolic blood pressure at week 68 are presented. Results are based on the data from the on-treatment observation period, which was the time period when a participant was on trial treatment, including any period after initiation of rescue medication.

    Time frame: Baseline (week 0), week 68

  37. Change From Baseline in Pulse (Week 52)

    Change from baseline (week 0) in pulse at week 52 are presented. Results are based on the data from the on-treatment observation period, which was the time period when a participant was on trial treatment, including any period after initiation of rescue medication.

    Time frame: Baseline (week 0), week 52

  38. Change From Baseline in Pulse (Week 68)

    Change from baseline (week 0) in pulse at week 68 are presented. Results are based on the data from the on-treatment observation period, which was the time period when a participant was on trial treatment, including any period after initiation of rescue medication.

    Time frame: Baseline (week 0), week 68

07

Results

Posted Apr 3, 2024

Participant flow

The trial was conducted in 14 countries (184 sites screened/177 randomised participants) as follows: Australia: 7/6; Bulgaria: 15/15; Canada: 13/13; Croatia: 5/5; Czech Republic: 5/5; Estonia: 6/5; Germany: 8/8; Hungary: 9/9; India: 20/20; Poland: 18/18; Slovakia: 9/9; Slovenia: 5/5; Taiwan: 2/2; United States: 62/57. In addition, Bulgaria (1 site), Canada (1 site), Croatia (1 site) and Poland (1 site) were approved by the institutional review board, but did not randomise any participant.

Participant flow — Overall Study
MilestoneOral Semaglutide 14 mgOral Semaglutide 25 mgOral Semaglutide 50 mg
Started536535535
Treated534534534
Full analysis set (fas)536535535
Safety analysis set (sas)534534534
Completed507490505
Not completed294530
Withdrew: Site closure020
Withdrew: Physician decision222
Withdrew: Death162
Withdrew: Lost to follow-up91914
Withdrew: Withdrawal by subject171612

Outcome measures

PrimaryChange From Baseline in Glycated Haemoglobin (HbA1c) (Week 52)

Change from baseline (week 0) in glycosylated haemoglobin (HbA1c) was evaluated at week 52. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of additional anti-diabetic medication or discontinuation of trial treatment. Percentage point refers to arithmetic difference between two percentages.

Time frame:
Baseline (week 0), week 52
Reported as:
Mean · Percentage point of HbA1c
Change From Baseline in Glycated Haemoglobin (HbA1c) (Week 52)
Percentage point of HbA1cOral Semaglutide 14 mgOral Semaglutide 25 mgOral Semaglutide 50 mg
Change From Baseline in Glycated Haemoglobin (HbA1c) (Week 52)-1.5 ± 1.3-1.9 ± 1.3-2.1 ± 1.4
Statistical analysis
  • Oral Semaglutide 14 mg vs Oral Semaglutide 25 mg · ANCOVA · p = 0.0006 (Unadjusted two-sided p-value for test of no difference.) · Treatment difference: -0.27 · 95% CI -0.42 to -0.12
  • Oral Semaglutide 14 mg vs Oral Semaglutide 50 mg · ANCOVA · p = <.0001 (Unadjusted two-sided p-value for test of no difference.) · Treatment difference: -0.53 · 95% CI -0.68 to -0.38
SecondaryChange From Baseline in Body Weight (Week 52)

Change from baseline (week 0) in body weight was evaluated at week 52. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of additional anti-diabetic medication or discontinuation of trial treatment.

Time frame:
Baseline (week 0), week 52
Reported as:
Mean · Kilogram (Kg)
Change From Baseline in Body Weight (Week 52)
Kilogram (Kg)Oral Semaglutide 14 mgOral Semaglutide 25 mgOral Semaglutide 50 mg
Change From Baseline in Body Weight (Week 52)-4.4 ± 5.2-7.1 ± 6.8-8.3 ± 7.5
SecondaryChange From Baseline in HbA1c (Week 68)

Change from baseline (week 0) in HbA1c was evaluated at week 68. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of additional anti-diabetic medication or discontinuation of trial treatment. Percentage point refers to arithmetic difference between two percentages.

Time frame:
Baseline (week 0), week 68
Reported as:
Mean · Percentage point of HbA1c
Change From Baseline in HbA1c (Week 68)
Percentage point of HbA1cOral Semaglutide 14 mgOral Semaglutide 25 mgOral Semaglutide 50 mg
Change From Baseline in HbA1c (Week 68)-1.5 ± 1.3-1.8 ± 1.3-2.0 ± 1.4
SecondaryChange From Week 12 in HbA1c (Week 52)

Change in HbA1c was evaluated from week 12 to week 52. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of additional anti-diabetic medication or discontinuation of trial treatment. Percentage point refers to arithmetic difference between two percentages.

Time frame:
Week 12, Week 52
Reported as:
Mean · Percentage point of HbA1c
Change From Week 12 in HbA1c (Week 52)
Percentage point of HbA1cOral Semaglutide 14 mgOral Semaglutide 25 mgOral Semaglutide 50 mg
Change From Week 12 in HbA1c (Week 52)-0.4 ± 1.2-0.8 ± 1.1-1.0 ± 1.2
SecondaryChange From Baseline in Fasting Plasma Glucose (FPG) (Week 52)

Change from baseline (week 0) in fasting plasma glucose (FPG) was evaluated at week 52. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of additional anti-diabetic medication or discontinuation of trial treatment.

Time frame:
Baseline (week 0), week 52
Reported as:
Mean · millimole per litre (mmol/L)
Change From Baseline in Fasting Plasma Glucose (FPG) (Week 52)
millimole per litre (mmol/L)Oral Semaglutide 14 mgOral Semaglutide 25 mgOral Semaglutide 50 mg
Change From Baseline in Fasting Plasma Glucose (FPG) (Week 52)-2.4 ± 3.4-3.0 ± 3.5-3.2 ± 3.4
SecondaryChange From Baseline in FPG (Week 68)

Change from baseline (week 0) in FPG was evaluated at week 68. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of additional anti-diabetic medication or discontinuation of trial treatment.

Time frame:
Baseline (week 0), week 68
Reported as:
Mean · mmol/L
Change From Baseline in FPG (Week 68)
mmol/LOral Semaglutide 14 mgOral Semaglutide 25 mgOral Semaglutide 50 mg
Change From Baseline in FPG (Week 68)-2.4 ± 3.4-3.0 ± 3.7-3.2 ± 3.4
SecondaryPercentage of Participants Who Achieved HbA1c Less Than (<) 7.0 (Percent [%]) (Week 52)

Percentage of participants who achieved HbA1c \<7.0 % at week 52 are presented. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of additional anti-diabetic medication or discontinuation of trial treatment.

Time frame:
At week 52
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Achieved HbA1c Less Than (<) 7.0 (Percent [%]) (Week 52)
Percentage of ParticipantsOral Semaglutide 14 mgOral Semaglutide 25 mgOral Semaglutide 50 mg
Percentage of Participants Who Achieved HbA1c Less Than (<) 7.0 (Percent [%]) (Week 52)3950.563
SecondaryPercentage of Participants Who Achieved HbA1c < 7.0 % (Week 68)

Percentage of participants who achieved HbA1c \<7.0 % at week 68 are presented. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of additional anti-diabetic medication or discontinuation of trial treatment.

Time frame:
At week 68
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Achieved HbA1c < 7.0 % (Week 68)
Percentage of ParticipantsOral Semaglutide 14 mgOral Semaglutide 25 mgOral Semaglutide 50 mg
Percentage of Participants Who Achieved HbA1c < 7.0 % (Week 68)39.249.958.9
SecondaryPercentage of Participants Who Achieved HbA1c Less Than or Equal to (<=) 6.5 % (Week 52)

Percentage of participants who achieved HbA1c \<=6.5 % at week 52 are presented. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of additional anti-diabetic medication or discontinuation of trial treatment.

Time frame:
At week 52
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Achieved HbA1c Less Than or Equal to (<=) 6.5 % (Week 52)
Percentage of ParticipantsOral Semaglutide 14 mgOral Semaglutide 25 mgOral Semaglutide 50 mg
Percentage of Participants Who Achieved HbA1c Less Than or Equal to (<=) 6.5 % (Week 52)25.839.651.2
SecondaryPercentage of Participants Who Achieved HbA1c <= 6.5 % (Week 68)

Percentage of participants who achieved HbA1c \<=6.5 % at week 68 are presented. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of additional anti-diabetic medication or discontinuation of trial treatment.

Time frame:
At week 68
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Achieved HbA1c <= 6.5 % (Week 68)
Percentage of ParticipantsOral Semaglutide 14 mgOral Semaglutide 25 mgOral Semaglutide 50 mg
Percentage of Participants Who Achieved HbA1c <= 6.5 % (Week 68)23.635.846.2
SecondaryTime to Event Analyses of Rescue Medication

Time to event analyses of rescue medication was evaluated from baseline (week 0) to week 68. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of additional anti-diabetic medication or discontinuation of trial treatment.

Time frame:
Baseline (week 0), week 68
Reported as:
Median · Weeks
Time to Event Analyses of Rescue Medication
WeeksOral Semaglutide 14 mgOral Semaglutide 25 mgOral Semaglutide 50 mg
Time to Event Analyses of Rescue MedicationNA (NA to NA)NA (NA to NA)NA (NA to NA)
SecondaryChange From Baseline in Body Weight (Week 68)

Change from baseline (week 0) in body weight was evaluated at week 68. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of additional anti-diabetic medication or discontinuation of trial treatment.

Time frame:
Baseline (week 0), week 68
Reported as:
Mean · Kg
Change From Baseline in Body Weight (Week 68)
KgOral Semaglutide 14 mgOral Semaglutide 25 mgOral Semaglutide 50 mg
Change From Baseline in Body Weight (Week 68)-4.5 ± 5.5-7.1 ± 7.4-8.2 ± 8.1
SecondaryPercentage Change From Baseline in Body Weight (Week 52)

Percentage change from baseline (week 0) in body weight was evaluated at week 52. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of additional anti-diabetic medication or discontinuation of trial treatment.

Time frame:
Baseline (week 0), week 52
Reported as:
Mean · Percentage change in body weight
Percentage Change From Baseline in Body Weight (Week 52)
Percentage change in body weightOral Semaglutide 14 mgOral Semaglutide 25 mgOral Semaglutide 50 mg
Percentage Change From Baseline in Body Weight (Week 52)-4.7 ± 5.4-7.3 ± 6.6-8.5 ± 7.3
SecondaryPercentage Change From Baseline in Body Weight (Week 68)

Percentage change from baseline (week 0) in body weight was evaluated at week 68. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of additional anti-diabetic medication or discontinuation of trial treatment.

Time frame:
Baseline (week 0), week 68
Reported as:
Mean · Percentage change in body weight
Percentage Change From Baseline in Body Weight (Week 68)
Percentage change in body weightOral Semaglutide 14 mgOral Semaglutide 25 mgOral Semaglutide 50 mg
Percentage Change From Baseline in Body Weight (Week 68)-4.7 ± 5.6-7.2 ± 7.1-8.4 ± 7.7
SecondaryPercentage Change From Week 12 in Body Weight (Week 52)

Percentage change in body weight was evaluated from week 12 to week 52. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of additional anti-diabetic medication or discontinuation of trial treatment.

Time frame:
Week 12, Week 52
Reported as:
Mean · Percentage change in body weight
Percentage Change From Week 12 in Body Weight (Week 52)
Percentage change in body weightOral Semaglutide 14 mgOral Semaglutide 25 mgOral Semaglutide 50 mg
Percentage Change From Week 12 in Body Weight (Week 52)-1.5 ± 3.6-3.8 ± 5.4-5.4 ± 6.1
SecondaryChange From Baseline in Body Mass Index (BMI) (Week 52)

Change from baseline (week 0) in body mass index (BMI) was evaluated at week 52. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of additional anti-diabetic medication or discontinuation of trial treatment.

Time frame:
Baseline (week 0), week 52
Reported as:
Mean · kilogram per square metre (kg/m^2)
Change From Baseline in Body Mass Index (BMI) (Week 52)
kilogram per square metre (kg/m^2)Oral Semaglutide 14 mgOral Semaglutide 25 mgOral Semaglutide 50 mg
Change From Baseline in Body Mass Index (BMI) (Week 52)-1.6 ± 1.8-2.5 ± 2.5-2.9 ± 2.6
SecondaryChange From Baseline in BMI (Week 68)

Change from baseline (week 0) in BMI was evaluated at week 68. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of additional anti-diabetic medication or discontinuation of trial treatment.

Time frame:
Baseline (week 0), week 68
Reported as:
Mean · kg/m^2
Change From Baseline in BMI (Week 68)
kg/m^2Oral Semaglutide 14 mgOral Semaglutide 25 mgOral Semaglutide 50 mg
Change From Baseline in BMI (Week 68)-1.6 ± 1.9-2.5 ± 2.7-2.9 ± 2.8
SecondaryChange From Baseline in Waist Circumference (Week 52)

Change from baseline (week 0) in waist circumference was evaluated at week 52. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of additional anti-diabetic medication or discontinuation of trial treatment.

Time frame:
Baseline (week 0), week 52
Reported as:
Mean · centimetre (cm)
Change From Baseline in Waist Circumference (Week 52)
centimetre (cm)Oral Semaglutide 14 mgOral Semaglutide 25 mgOral Semaglutide 50 mg
Change From Baseline in Waist Circumference (Week 52)-4 ± 7-5 ± 7-6 ± 7
SecondaryChange From Baseline in Waist Circumference (Week 68)

Change from baseline (week 0) in waist circumference was evaluated at week 68. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of additional anti-diabetic medication or discontinuation of trial treatment.

Time frame:
Baseline (week 0), week 68
Reported as:
Mean · cm
Change From Baseline in Waist Circumference (Week 68)
cmOral Semaglutide 14 mgOral Semaglutide 25 mgOral Semaglutide 50 mg
Change From Baseline in Waist Circumference (Week 68)-4 ± 6-6 ± 7-7 ± 8
SecondaryPercentage of Participants Who Achieved Weight Loss Greater Than or Equal to (>=) 5 % (Week 52)

Percentage of participants who achieved weight loss \>= 5 % at week 52 are presented. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of additional anti-diabetic medication or discontinuation of trial treatment.

Time frame:
At week 52
Reported as:
Number · Percentage of participants
Percentage of Participants Who Achieved Weight Loss Greater Than or Equal to (>=) 5 % (Week 52)
Percentage of participantsOral Semaglutide 14 mgOral Semaglutide 25 mgOral Semaglutide 50 mg
Percentage of Participants Who Achieved Weight Loss Greater Than or Equal to (>=) 5 % (Week 52)416067.5
SecondaryPercentage of Participants Who Achieved Weight Loss >= 5 % (Week 68)

Percentage of participants who achieved weight loss \>= 5 % at week 68 are presented. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of additional anti-diabetic medication or discontinuation of trial treatment.

Time frame:
At week 68
Reported as:
Number · Percentage of participants
Percentage of Participants Who Achieved Weight Loss >= 5 % (Week 68)
Percentage of participantsOral Semaglutide 14 mgOral Semaglutide 25 mgOral Semaglutide 50 mg
Percentage of Participants Who Achieved Weight Loss >= 5 % (Week 68)42.258.565.7
SecondaryPercentage of Participants Who Achieved Weight Loss >= 10 % (Week 52)

Percentage of participants who achieved weight loss \>= 10 % at week 52 are presented. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of additional anti-diabetic medication or discontinuation of trial treatment.

Time frame:
At week 52
Reported as:
Number · Percentage of participants
Percentage of Participants Who Achieved Weight Loss >= 10 % (Week 52)
Percentage of participantsOral Semaglutide 14 mgOral Semaglutide 25 mgOral Semaglutide 50 mg
Percentage of Participants Who Achieved Weight Loss >= 10 % (Week 52)13.92937.2
SecondaryPercentage of Participants Who Achieved Weight Loss >= 10 % (Week 68)

Percentage of participants who achieved weight loss \>= 10 % at week 68 are presented. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of additional anti-diabetic medication or discontinuation of trial treatment.

Time frame:
At week 68
Reported as:
Number · Percentage of participants
Percentage of Participants Who Achieved Weight Loss >= 10 % (Week 68)
Percentage of participantsOral Semaglutide 14 mgOral Semaglutide 25 mgOral Semaglutide 50 mg
Percentage of Participants Who Achieved Weight Loss >= 10 % (Week 68)14.329.434.7
SecondaryChange From Baseline in Total Cholesterol (Week 52)

Change from baseline (week 0) in total cholesterol was evaluated at week 52. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of additional anti-diabetic medication or discontinuation of trial treatment.

Time frame:
Baseline, Week 52
Reported as:
Mean · mmol/L
Change From Baseline in Total Cholesterol (Week 52)
mmol/LOral Semaglutide 14 mgOral Semaglutide 25 mgOral Semaglutide 50 mg
Change From Baseline in Total Cholesterol (Week 52)-0.04 ± 0.96-0.15 ± 1.10-0.06 ± 0.94
SecondaryChange From Baseline in Total Cholesterol (Week 68)

Change from baseline (week 0) in total cholesterol was evaluated at week 68. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of additional anti-diabetic medication or discontinuation of trial treatment.

Time frame:
Baseline, Week 68
Reported as:
Mean · mmol/L
Change From Baseline in Total Cholesterol (Week 68)
mmol/LOral Semaglutide 14 mgOral Semaglutide 25 mgOral Semaglutide 50 mg
Change From Baseline in Total Cholesterol (Week 68)-0.03 ± 0.99-0.08 ± 1.05-0.06 ± 1.00
SecondaryChange From Baseline in Low Density Lipoproteins (LDL) (Week 52)

Change from baseline (week 0) in LDL was evaluated at week 52. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of additional anti-diabetic medication or discontinuation of trial treatment.

Time frame:
Baseline, Week 52
Reported as:
Mean · mmol/L
Change From Baseline in Low Density Lipoproteins (LDL) (Week 52)
mmol/LOral Semaglutide 14 mgOral Semaglutide 25 mgOral Semaglutide 50 mg
Change From Baseline in Low Density Lipoproteins (LDL) (Week 52)0.04 ± 0.75-0.01 ± 0.850.11 ± 0.76
SecondaryChange From Baseline in LDL (Week 68)

Change from baseline (week 0) in LDL was evaluated at week 68. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of additional anti-diabetic medication or discontinuation of trial treatment.

Time frame:
Baseline, Week 68
Reported as:
Mean · mmol/L
Change From Baseline in LDL (Week 68)
mmol/LOral Semaglutide 14 mgOral Semaglutide 25 mgOral Semaglutide 50 mg
Change From Baseline in LDL (Week 68)0.07 ± 0.800.06 ± 0.850.08 ± 0.79
SecondaryChange From Baseline in High Density Lipoproteins (HDL) (Week 52)

Change from baseline (week 0) in HDL was evaluated at week 52. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of additional anti-diabetic medication or discontinuation of trial treatment.

Time frame:
Baseline, Week 52
Reported as:
Mean · mmol/L
Change From Baseline in High Density Lipoproteins (HDL) (Week 52)
mmol/LOral Semaglutide 14 mgOral Semaglutide 25 mgOral Semaglutide 50 mg
Change From Baseline in High Density Lipoproteins (HDL) (Week 52)0.06 ± 0.180.07 ± 0.190.08 ± 0.18
SecondaryChange From Baseline in HDL (Week 68)

Change from baseline (week 0) in HDL was evaluated at week 68. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of additional anti-diabetic medication or discontinuation of trial treatment.

Time frame:
Baseline, Week 68
Reported as:
Mean · mmol/L
Change From Baseline in HDL (Week 68)
mmol/LOral Semaglutide 14 mgOral Semaglutide 25 mgOral Semaglutide 50 mg
Change From Baseline in HDL (Week 68)0.06 ± 0.190.08 ± 0.210.09 ± 0.20
SecondaryChange From Baseline in Triglycerides (Week 52)

Change from baseline (week 0) in triglycerides was evaluated at week 52. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of additional anti-diabetic medication or discontinuation of trial treatment.

Time frame:
Baseline, Week 52
Reported as:
Mean · mmol/L
Change From Baseline in Triglycerides (Week 52)
mmol/LOral Semaglutide 14 mgOral Semaglutide 25 mgOral Semaglutide 50 mg
Change From Baseline in Triglycerides (Week 52)-0.46 ± 1.77-0.65 ± 2.08-0.71 ± 1.40
SecondaryChange From Baseline in Triglycerides (Week 68)

Change from baseline (week 0) in triglycerides was evaluated at week 68. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of additional anti-diabetic medication or discontinuation of trial treatment.

Time frame:
Baseline, Week 68
Reported as:
Mean · mmol/L
Change From Baseline in Triglycerides (Week 68)
mmol/LOral Semaglutide 14 mgOral Semaglutide 25 mgOral Semaglutide 50 mg
Change From Baseline in Triglycerides (Week 68)-0.51 ± 1.77-0.65 ± 2.06-0.70 ± 1.43
SecondaryNumber of Adverse Events

An adverse event (AE) defined as any unfavourable and unintended sign, including an abnormal laboratory finding, symptom or disease (new or exacerbated) temporally associated with the use of an investigational medicinal products (IMP). Results are based on the data from the on-treatment observation period, which was the time period when a participant was on trial treatment, including any period after initiation of rescue medication.

Time frame:
From baseline (week 0) up to week 73
Reported as:
Number · Events
Number of Adverse Events
EventsOral Semaglutide 14 mgOral Semaglutide 25 mgOral Semaglutide 50 mg
Number of Adverse Events164120552115
SecondaryNumber of Clinically Significant Hypoglycaemic Episodes (Level 2) (<3.0 mmol/L (54 Milligram Per Decilitre [mg/dL]) or Severe Hypoglycaemic Episodes (Level 3)

Hypoglycaemic episodes were classified according to the American Diabetes Association 2018/ International Hypoglycaemia Study Group 2017, where glycemic criteria for level 2 was \< 3.0 mmol/L (54 mg/dL) and level 3 had no specific glucose threshold. Results are based on the data from the on-treatment observation period, which was the time period when a participant was on trial treatment, including any period after initiation of rescue medication.

Time frame:
From baseline (week 0) up to week 68
Reported as:
Number · Count of episodes
Number of Clinically Significant Hypoglycaemic Episodes (Level 2) (<3.0 mmol/L (54 Milligram Per Decilitre [mg/dL]) or Severe Hypoglycaemic Episodes (Level 3)
Count of episodesOral Semaglutide 14 mgOral Semaglutide 25 mgOral Semaglutide 50 mg
Level 2654435
Level 3001
SecondaryChange From Baseline in Systolic Blood Pressure (Week 52)

Change from baseline (week 0) in systolic blood pressure at week 52 are presented. Results are based on the data from the on-treatment observation period, which was the time period when a participant was on trial treatment, including any period after initiation of rescue medication.

Time frame:
Baseline (week 0), week 52
Reported as:
Mean · millimetres of mercury (mmHg)
Change From Baseline in Systolic Blood Pressure (Week 52)
millimetres of mercury (mmHg)Oral Semaglutide 14 mgOral Semaglutide 25 mgOral Semaglutide 50 mg
Change From Baseline in Systolic Blood Pressure (Week 52)-4 ± 14-6 ± 13-6 ± 14
SecondaryChange From Baseline in Systolic Blood Pressure (Week 68)

Change from baseline (week 0) in systolic blood pressure at week 68 are presented. Results are based on the data from the on-treatment observation period, which was the time period when a participant was on trial treatment, including any period after initiation of rescue medication.

Time frame:
Baseline (week 0), week 68
Reported as:
Mean · mmHg
Change From Baseline in Systolic Blood Pressure (Week 68)
mmHgOral Semaglutide 14 mgOral Semaglutide 25 mgOral Semaglutide 50 mg
Change From Baseline in Systolic Blood Pressure (Week 68)-4 ± 13-6 ± 13-5 ± 13
SecondaryChange From Baseline in Diastolic Blood Pressure (Week 52)

Change from baseline (week 0) in diastolic blood pressure at week 52 are presented. Results are based on the data from the on-treatment observation period, which was the time period when a participant was on trial treatment, including any period after initiation of rescue medication.

Time frame:
Baseline (week 0), week 52
Reported as:
Mean · mmHg
Change From Baseline in Diastolic Blood Pressure (Week 52)
mmHgOral Semaglutide 14 mgOral Semaglutide 25 mgOral Semaglutide 50 mg
Change From Baseline in Diastolic Blood Pressure (Week 52)-2 ± 8-2 ± 8-2 ± 8
SecondaryChange From Baseline in Diastolic Blood Pressure (Week 68)

Change from baseline (week 0) in diastolic blood pressure at week 68 are presented. Results are based on the data from the on-treatment observation period, which was the time period when a participant was on trial treatment, including any period after initiation of rescue medication.

Time frame:
Baseline (week 0), week 68
Reported as:
Mean · mmHg
Change From Baseline in Diastolic Blood Pressure (Week 68)
mmHgOral Semaglutide 14 mgOral Semaglutide 25 mgOral Semaglutide 50 mg
Change From Baseline in Diastolic Blood Pressure (Week 68)-3 ± 8-3 ± 8-2 ± 8
SecondaryChange From Baseline in Pulse (Week 52)

Change from baseline (week 0) in pulse at week 52 are presented. Results are based on the data from the on-treatment observation period, which was the time period when a participant was on trial treatment, including any period after initiation of rescue medication.

Time frame:
Baseline (week 0), week 52
Reported as:
Mean · beats per minute (beats/min)
Change From Baseline in Pulse (Week 52)
beats per minute (beats/min)Oral Semaglutide 14 mgOral Semaglutide 25 mgOral Semaglutide 50 mg
Change From Baseline in Pulse (Week 52)2 ± 102 ± 103 ± 11
SecondaryChange From Baseline in Pulse (Week 68)

Change from baseline (week 0) in pulse at week 68 are presented. Results are based on the data from the on-treatment observation period, which was the time period when a participant was on trial treatment, including any period after initiation of rescue medication.

Time frame:
Baseline (week 0), week 68
Reported as:
Mean · beats/min
Change From Baseline in Pulse (Week 68)
beats/minOral Semaglutide 14 mgOral Semaglutide 25 mgOral Semaglutide 50 mg
Change From Baseline in Pulse (Week 68)1 ± 102 ± 102 ± 10

Adverse events

Collected over Week 0 to week 73. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Oral Semaglutide 14 mg2/534 (0.4%)53/534 (9.9%)277/534 (51.9%)
Oral Semaglutide 25 mg6/534 (1.1%)57/534 (10.7%)294/534 (55.1%)
Oral Semaglutide 50 mg2/534 (0.4%)44/534 (8.2%)314/534 (58.8%)
Most frequent serious events
Showing 10 of 154
Most frequent serious events
EventOral Semaglutide 14 mgOral Semaglutide 25 mgOral Semaglutide 50 mg
Acute myocardial infarctionCardiac disorders4/5343/5341/534
COVID-19Infections and infestations3/5340/5343/534
Atrial fibrillationCardiac disorders2/5341/5341/534
COVID-19 pneumoniaInfections and infestations2/5342/5342/534
Cervical spinal stenosisMusculoskeletal and connective tissue disorders2/5340/5340/534
Circulatory collapseVascular disorders0/5342/5340/534
Coronary artery diseaseCardiac disorders2/5341/5341/534
Diabetic metabolic decompensationMetabolism and nutrition disorders0/5342/5340/534
Ischaemic strokeNervous system disorders1/5342/5340/534
Myocardial infarctionCardiac disorders2/5341/5340/534
Most frequent other events
Showing 10 of 12
Most frequent other events
EventOral Semaglutide 14 mgOral Semaglutide 25 mgOral Semaglutide 50 mg
NauseaGastrointestinal disorders96/534145/534146/534
VomitingGastrointestinal disorders52/53491/53497/534
DiarrhoeaGastrointestinal disorders66/53469/53476/534
COVID-19Infections and infestations63/53464/53466/534
Decreased appetiteMetabolism and nutrition disorders38/53439/53458/534
Diabetic retinopathyEye disorders41/53426/53435/534
ConstipationGastrointestinal disorders40/53435/53433/534
HeadacheNervous system disorders34/53428/53438/534
Abdominal pain upperGastrointestinal disorders14/53432/53422/534
DyspepsiaGastrointestinal disorders28/53429/53430/534

Baseline characteristics

Full analysis set (FAS) included all randomised participants.

Age, Continuous
Age, Continuous(Years)Oral Semaglutide 14 mgOral Semaglutide 25 mgOral Semaglutide 50 mgTotal
Mean58.4 ± 10.458.8 ± 10.757.6 ± 11.258.2 ± 10.8
Sex: Female, Male
Sex: Female, Male(Participants)Oral Semaglutide 14 mgOral Semaglutide 25 mgOral Semaglutide 50 mgTotal
Female211231228670
Male325304307936
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Oral Semaglutide 14 mgOral Semaglutide 25 mgOral Semaglutide 50 mgTotal
Hispanic or Latino383736111
Not Hispanic or Latino4984984991495
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Oral Semaglutide 14 mgOral Semaglutide 25 mgOral Semaglutide 50 mgTotal
American Indian or Alaska Native1001
Asian8573111269
Native Hawaiian or Other Pacific Islander0202
Black or African American19221859
White4244323981254
More than one race0000
Unknown or Not Reported76821
08

Study locations

228 sites
  • American Clinical Trials
    Buena Park, California 90620, United States
  • Valley Research
    Fresno, California 93720, United States
  • Velocity Clin Res San Diego
    La Mesa, California 91942, United States
  • First Valley Medical Group
    Lancaster, California 93534, United States
  • Pacific Clinical Studies
    Los Alamitos, California 90720, United States
  • Velocity Clin Res Los Angeles
    Los Angeles, California 90017, United States
  • Diabetes Medical Center Of California
    Northridge, California 91325, United States
  • Desert Oasis Hlthcr Med Group
    Palm Springs, California 92262, United States
  • Gateway Research Center
    Poway, California 92064, United States
  • Encompass Clinical Research_Spring Valley
    Spring Valley, California 91978, United States
  • Diablo Clinical Research, Inc.
    Walnut Creek, California 94598, United States
  • San Fernando Valley Hlth Inst, LLC
    West Hills, California 91304, United States
  • University of Colorado Hospital
    Aurora, Colorado 80045, United States
  • Optumcare Clinical Trials,LLC-Golden
    Colorado Springs, Colorado 80906, United States
  • Chase Medical Research LLC
    Waterbury, Connecticut 06708, United States
  • Alliance for Multispec Res
    Coral Gables, Florida 33134, United States
  • Northeast Research Institute
    Jacksonville, Florida 32204, United States
  • San Marcus Res Clin Miami Lakes
    Miami Lakes, Florida 33014, United States
  • Complete Health Research
    Ormond Beach, Florida 32174-6302, United States
  • Clinical Trial Res Assoc,Inc
    Plantation, Florida 33324, United States
  • Progressive Medical Research
    Port Orange, Florida 32127, United States
  • Endo Res Solutions Inc
    Roswell, Georgia 30076, United States
  • East West Med Res Inst
    Honolulu, Hawaii 96814, United States
  • Elite Clinical Trials
    Blackfoot, Idaho 83221, United States
  • Rocky Mt Clin Res, LLC
    Idaho Falls, Idaho 83404-7596, United States
  • Solaris Clinical Research
    Meridian, Idaho 83646, United States
  • Cedar-Crosse Research Center
    Chicago, Illinois 60607, United States
  • Macoupin Research Group
    Gillespie, Illinois 62033, United States
  • UnityPoint Health-Diabetes Care Center
    Peoria, Illinois 61603, United States
  • Evanston Premier Hlthcr Res
    Skokie, Illinois 60077, United States
  • Midwest Inst For Clin Res
    Indianapolis, Indiana 46260, United States
  • Iowa Diab & Endo Res Center
    West Des Moines, Iowa 50266, United States
  • Cotton O'Neil Diab & Endo Ctr
    Topeka, Kansas 66606, United States
  • The Research Group of Lexington LLC
    Lexington, Kentucky 40503, United States
  • L-MARC Research Center
    Louisville, Kentucky 40213, United States
  • Pennington Biom Res Ctr
    Baton Rouge, Louisiana 70808, United States
  • Centex Studies, Inc._Lake Charles
    Lake Charles, Louisiana 70601, United States
  • MD Medical Research
    Oxon Hill, Maryland 20745, United States
  • Brigham & Women's Hospital
    Boston, Massachusetts 02115-5804, United States
  • MassResearch, LLC
    Waltham, Massachusetts 02453, United States
  • Aa Mrc Llc
    Flint, Michigan 48504, United States
  • Arcturus Healthcare, PLC.
    Troy, Michigan 48098, United States
  • Mercury Str Med Grp, PLLC
    Butte, Montana 59701, United States
  • Univ of Nebraska Medical CTR
    Omaha, Nebraska 68198-3020, United States
  • University of Nebraska Medical Center-Diabetes Center
    Omaha, Nebraska 68198-4120, United States
  • Premier Research Inc.
    Trenton, New Jersey 08611, United States
  • UNC Diabetes Care Center_Chapel Hill
    Chapel Hill, North Carolina 27514, United States
  • PharmQuest Life Sciences LLC
    Greensboro, North Carolina 27408, United States
  • Accellacare
    Wilmington, North Carolina 28401, United States
  • Lillestol Research LLC
    Fargo, North Dakota 58104, United States
  • Rapid Medical Research Inc
    Cleveland, Ohio 44122, United States
  • Prestige Clinical Research
    Franklin, Ohio 45005, United States
  • Albert J Weisbrot
    Mason, Ohio 45040, United States
  • Intend Research
    Norman, Oklahoma 73069, United States
  • Corvallis Clinic PC Clinical Research Department
    Corvallis, Oregon 97330-3737, United States
  • Preferred Primary Care Physicians_Pittsburgh
    Pittsburgh, Pennsylvania 15236, United States
  • Palmetto Clinical Research
    Greenville, South Carolina 29615, United States
  • Palmetto Clinical Research
    Summerville, South Carolina 29485, United States
  • Holston Medical Group Pc
    Bristol, Tennessee 37620-7352, United States
  • Chattanooga Medical Research, LLC
    Chattanooga, Tennessee 37404, United States
  • Murphy Research Center
    Humboldt, Tennessee 38343, United States
  • Clinical Neuroscience Solutions
    Memphis, Tennessee 38119, United States
  • Arlington Family Res. Ctr Inc
    Arlington, Texas 76012-4637, United States
  • Velocity Clinical Res-Dallas
    Dallas, Texas 75230, United States
  • Velocity Clinical Research, Dallas
    Dallas, Texas 75230, United States
  • UT Southwestern Med Cntr
    Dallas, Texas 75390-9302, United States
  • Care United Research, LLC
    Forney, Texas 75126, United States
  • JCCT- Juno NW Houston
    Houston, Texas 77040, United States
  • JCCT- Juno NW Houston
    Houston, Texas 77074, United States
  • Southwest Clinical Trials
    Houston, Texas 77074, United States
  • Family Practice Care Associates
    Humble, Texas 77338, United States
  • Research Trials Worldwide LLC
    Humble, Texas 77338, United States
  • Juno Research, LLC_Cary
    Katy, Texas 77450, United States
  • DCOL Ctr for Clin Res
    Longview, Texas 75605, United States
  • Research Institute Of Dallas
    Plano, Texas 75093, United States
  • VIP Trials
    San Antonio, Texas 78230, United States
  • VIP Trials
    San Antonio, Texas 78231, United States
  • Consano Clinical Research, LLC
    Shavano Park, Texas 78231, United States
  • Simcare Medical Research, LLC
    Sugar Land, Texas 77478, United States
  • Health Res of Hampton Roads
    Newport News, Virginia 23606, United States
  • York Clinical Research LLC
    Norfolk, Virginia 23504, United States
  • Dominion Medical Associates
    Richmond, Virginia 23219, United States
  • Capital Clin Res Ctr,LLC
    Olympia, Washington 98502, United States
  • Wenatchee Valley Hospital and Clinics
    Wenatchee, Washington 98801-2028, United States
  • Liverpool Hospital
    Liverpool, New South Wales 2170, Australia
  • Royal Brisbane and Women's Hospital
    Herston, Queensland 4029, Australia
  • Core Research Centre
    Milton, Queensland 4064, Australia
  • South Australian Endocrine Research
    Keswick, South Australia 5035, Australia
  • Southern Adelaide Diabetes & Endocrine Services
    Oaklands Park, South Australia 5046, Australia
  • Barwon Health (The Geelong Hospital)
    Geelong, Victoria 3220, Australia
  • Fremantle Hospital
    Fremantle, Western Australia 6160, Australia
  • MHAT - Blagoevgrad AD, Department of Internal Diseases
    Blagoevgrad, 2700, Bulgaria
  • Medical Center Zdrave Lom EOOD
    Lom, 3600, Bulgaria
  • UMHAT Pulmed OOD - Pazardzhik, Department of Internal Diseases
    Pazardzhik, 4400, Bulgaria
  • "MHAT - Pazardzhik"
    Pazardzhik, 4401, Bulgaria
  • OCSOMCE - Dr. Albena Dinkova EOOD
    Pleven, 5800, Bulgaria
  • UMHAT Kaspela EOOD, Endocrinology and Metabolic Diseases Clinic
    Plovdiv, 4001, Bulgaria
  • MHAT Sveta Karidad EAD
    Plovdiv, 4004, Bulgaria
  • MHAT Hadzhi Dimitar OOD
    Sliven, 8800, Bulgaria
  • Medical center Smolyan clinical research OOD
    Smolyan, 4700, Bulgaria

Showing the first 100 of 228 sites across 15 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Aroda VR, Aberle J, Bardtrum L, Christiansen E, Knop FK, Gabery S, Pedersen SD, Buse JB. Efficacy and safety of once-daily oral semaglutide 25 mg and 50 mg compared with 14 mg in adults with type 2 diabetes (PIONEER PLUS): a multicentre, randomised, phase 3b trial. Lancet. 2023 Aug 26;402(10403):693-704. doi: 10.1016/S0140-6736(23)01127-3. Epub 2023 Jun 26. PubMed 37385279 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com

Data sharing details ↗ · novonordisk-trials.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2021 to primary completion in Mar 2023, 25 months.

Results were first posted in Apr 2024, 1 year after primary completion.

Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 25 months is above that.

Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 12, 2021
First posted
Jan 13, 2021
StartActual
Jan 15, 2021
Primary completionActual
Mar 7, 2023
CompletionActual
Mar 8, 2023
Results first posted
Apr 3, 2024
Last update
Dec 9, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 9, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04707469
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Jan 13, 2021
Start date
Jan 15, 2021
Primary completion
Mar 7, 2023
Completion
Mar 8, 2023
Results posted
Apr 3, 2024
Last update
Dec 9, 2025

Study contacts

Clinical Transparency (dept. 1452)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Semaglutide

Start the discussion